Stocks News

LAST PRICE
20.2000
TODAY'S CHANGE (%)
Trending Up0.5800 (2.9562%)

Bid / Lots
20.2000/ 2
Ask / Lots
20.5000/ 1
Open / Previous Close
19.4400 / 19.6200
Day Range
Low 19.4400
High 20.2200
52 Week Range
Low 11.4000
High 27.2000
Volume
858,390
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 14, 2024
- DJ Viridian Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 5:18AM ET on Thursday Nov 14, 2024 by Dow Jones
  5:18AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: VRDN
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/VRDN/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 14, 2024 05:18 ET (10:18 GMT)
Nov 13, 2024
- DJ Viridian Therapeutics Price Target Maintained With a $38.00/Share by Needham, from 5:16AM ET on Wednesday Nov 13, 2024 by Dow Jones
  5:16AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: VRDN
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/VRDN/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 13, 2024 05:16 ET (10:16 GMT)
Nov 12, 2024
- Wedbush Raises Viridian Therapeutics' Price Target to $48 From $45, Maintains Outperform Rating, from 2:49PM ET on Tuesday Nov 12, 2024 by MT Newswires
  2:49PM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: VRDN
  02:49 PM EST, 11/12/2024 (MT Newswires) -- Viridian Therapeutics (VRDN) has an average rating of Buy and price targets ranging from $22 to $56, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research ...
- Viridian Therapeutics Q3 Net Loss Widens, Revenue Rises; Shares Up Pre-Bell, from 8:54AM ET on Tuesday Nov 12, 2024 by MT Newswires
  8:54AM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: VRDN
  08:54 AM EST, 11/12/2024 (MT Newswires) -- Viridian Therapeutics (VRDN) reported a Q3 net loss Tuesday of $1.15 per diluted share, compared with a loss of $1.09 a year earlier. Analysts polled by Capital IQ expected a loss of $1.07 Revenue for the q...
- -- Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q3 Revenue $86,000, from 7:01AM ET on Tuesday Nov 12, 2024 by MT Newswires
  7:01AM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: VRDN
  07:01 AM EST, 11/12/2024 (MT Newswires) -- ...

Today
- DJ Neumora Therapeutics Price Target Maintained With a $29.00/Share by RBC Capital, from 9 hours ago by Dow Jones
  9 hours ago by Dow Jones
  Companies Mentioned: NMRA
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE, from 10 hours ago by Accesswire
  10 hours ago by Accesswire
  Companies Mentioned: SYRE
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE, from 10 hours ago by Dow Jones
  10 hours ago by Dow Jones
  Companies Mentioned: SYRE
- Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation, from 11 hours ago by Accesswire
  11 hours ago by Accesswire
  Companies Mentioned: SYRE
- Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation, from 11 hours ago by Dow Jones
  11 hours ago by Dow Jones
  Companies Mentioned: SYRE
Yesterday
- Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation, from 2:01PM ET on Thursday Nov 21, 2024 by Accesswire
  2:01PM ET on Thursday Nov 21, 2024 by Accesswire
  Companies Mentioned: SYRE
- Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation, from 10:01AM ET on Thursday Nov 21, 2024 by Dow Jones
  10:01AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: SYRE
Nov 20, 2024
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE, from 10:02AM ET on Wednesday Nov 20, 2024 by Dow Jones
  10:02AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: SYRE
- Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out, from 10:02AM ET on Wednesday Nov 20, 2024 by Dow Jones
  10:02AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: SYRE
Nov 19, 2024
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE, from 3:15PM ET on Tuesday Nov 19, 2024 by Dow Jones
  3:15PM ET on Tuesday Nov 19, 2024 by Dow Jones
  Companies Mentioned: SYRE

Viridian Therapeutics Inc
NASDAQ:VRDNUnited States

Search Criteria

Nov 14, 2024

DJ Viridian Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 5:18AM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

DJ Viridian Therapeutics Price Target Maintained With a $38.00/Share by Needham, from 5:16AM ET on Wednesday Nov 13, 2024 by Dow Jones

Nov 12, 2024

Wedbush Raises Viridian Therapeutics' Price Target to $48 From $45, Maintains Outperform Rating, from 2:49PM ET on Tuesday Nov 12, 2024 by MT Newswires

Viridian Therapeutics Q3 Net Loss Widens, Revenue Rises; Shares Up Pre-Bell, from 8:54AM ET on Tuesday Nov 12, 2024 by MT Newswires

-- Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q3 Revenue $86,000, from 7:01AM ET on Tuesday Nov 12, 2024 by MT Newswires

Peers Headlines

Today

DJ Neumora Therapeutics Price Target Maintained With a $29.00/Share by RBC Capital, from 9 hours ago by Dow Jones

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE, from 10 hours ago by Accesswire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE, from 10 hours ago by Dow Jones

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation, from 11 hours ago by Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation, from 11 hours ago by Dow Jones

Yesterday

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation, from 2:01PM ET on Thursday Nov 21, 2024 by Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation, from 10:01AM ET on Thursday Nov 21, 2024 by Dow Jones

Nov 20, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE, from 10:02AM ET on Wednesday Nov 20, 2024 by Dow Jones

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out, from 10:02AM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 19, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE, from 3:15PM ET on Tuesday Nov 19, 2024 by Dow Jones